Abstract
BACKGROUND Past studies have mainly focused on total bilirubin levels, and have not clearly distinguished between direct and indirect bilirubin, a subgroup of bilirubin. In this study, the differences between these subgroups were clearly examined, and the causal association with ischemic stroke was examined in more detail.
METHODS Utilizing Two sample Multivariable Mendelian randomization (MVMR) analyses, summary data for bilirubin were extracted from the KCPS-II (Korean Cancer Prevention Study-II; n=159,844) and the KoGES (Korean Genome and Epidemiology Study; n=72,299), while ischemic stroke data were derived from the BBJ (Bio Bank Japan; n=201,800).
RESULTS The crude two-sample MR analysis revealed a significant negative association between total bilirubin and ischemic stroke in KoGES data (odds ratio [OR], 0.86; 95% confidence interval [CI], 0.75-0.98). Subsequent bivariable MR analyses, controlling for lipid profile, also showed significant results. In KCPS-II data, direct bilirubin showed significance in both crude (0.65, 0.43-0.97) and bivariable analyses, while indirect bilirubin demonstrated significant associations in MVMR analyses (0.76, 0.59-0.98), emphasizing its role in mitigating the risk of ischemic stroke.
CONCLUSIONS Our study establishes a causal association between genetically determined levels of serum bilirubin (total, direct, and indirect) and a reduced risk of ischemic stroke in an Asian population. Notably, the protective effect was predominantly associated with indirect bilirubin. The findings highlight the significance of considering bilirubin subgroup in understanding the mechanisms underlying endogenous antioxidants and its impact on ischemic stroke.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI20C0517).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol was approved by the Institutional Review Board of the Severance Hospital (approval number: 4-2011-0277).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data availability statement When a paper is published, summary data are available.
